Navigation Links
RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model of breast cancer and that the drug inhibits signaling activity of STAT3, an important target for new cancer therapies.

The article, "The Novel Triterpenoid C-28 Methyl Ester of 2-Cyano-3, 12-Dioxooleen-1, 9-Dien-28-Oic Acid Inhibits Metastatic Murine Breast Tumor Growth through Inactivation of STAT3 Signaling," was authored by Reata scientific collaborators from the University of Texas M. D. Anderson Cancer Center.

The authors conducted two studies of RTA 402 in the highly rigorous 4T1 mouse model of breast cancer. Few other agents have shown any effect in this animal model, in which tumors grow very rapidly and become widely distributed, or metastasized, throughout the body. In two separate experiments, treatment with RTA 402 was found to have a profound effect in suppressing the growth and spread of these tumors. In a model mimicking the spread of metastatic disease, RTA 402 completely blocked the development of metastases in all animals, whereas untreated animals developed widespread disease. In a second model mimicking the treatment of established breast tumors, RTA 402 provided a 95% reduction in the total tumor burden of treated animals compared with the untreated control group.

Additionally, the authors showed that this activity was occurring in part through inactivation of STAT3 signaling. STAT3 - short for signal transducer and activator of transcription 3 - is increasingly recognized as an important target for cancer therapies. Activated STAT3 is frequently found in patients with breast cancer and other types of tumors. This protein is known to turn on a number of genes associated with cancer
'"/>




Page: 1 2 3

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
(Date:9/22/2014)... NEW YORK , September 22, 2014 ... New Market Report on "Global Market Study on Ophthalmic ... Growth by 2020," the global ophthalmic devices market was valued at ... grow at a CAGR of 6.5% from 2014 to ... million in 2020. Browse the full Global Market ...
(Date:9/22/2014)...  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... University, presented long-term follow up data on the Phase ... the treatment of amyotrophic lateral sclerosis (ALS or ... the Annual Symposium on ALS of the Foundation Andre-Delambre, ... and was not open to the public, covered data ...
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
... (Nasdaq: BMRN ) today announced that Joshua Grass, ... a company update at the UBS Global Life Sciences Conference ... 3:30 p.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Arcion Therapeutics , a venture backed clinical stage ... announced that the U.S. Food and Drug Administration (FDA) ... treatment of pain associated with Painful Diabetic Neuropathy (PDN). ... for topical administration. Arcion recently announced positive ...
Cached Medicine Technology:BioMarin to Present at the UBS Global Life Sciences Conference 2Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy 2
(Date:9/22/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
(Date:9/22/2014)... 2014. Kessler researchers have published a pilot study ... program in people with multiple sclerosis (MS). ... perceived stress, and pain. "Development and effectiveness ... with MS: Description and outcomes" was epublished ahead ... International Journal of MS Care (doi: 10.7224/1537-2073.2013-045). ...
(Date:9/22/2014)... 22, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announced findings from its recent industry survey on ... (HPID) within electronic transactions adopted under the Health ... the survey from August 20 to September 5, ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay ... It,s something every pregnant woman wonders: What can I do ... that taking iron supplements as prescribed may play a role ... spectrum disorder (ASD). The researchers found that mothers of ... iron supplements before and during pregnancy than those whose children ...
Breaking Medicine News(10 mins):Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... Centers for,Medicare & Medicaid Services (CMS) has selected the ... data analysis,services to detect potential fraud and waste in ... task order to help identify inappropriate,and unnecessary Medicaid payments ... MIP was created as a result of the federal ...
... MED, CEO DeCODE Genetics, WASHINGTON, June 5 ... Cardiovascular Institute:, Date: Thursday, June 12, 2008, ... 23rd Street, NW, Time: Noon - 2:50pm, ... Dr. Stefansson is CEO and co-founder of deCODE genetics ...
... MA Researchers from Boston University School of Medicine (BUSM) ... among Medicare beneficiaries at the end of life. The ... Internal Medicine. , According to researchers, medical treatments for ... year comprise almost 30 percent of Medicare expenditures. In ...
... Visit Denver to Rally Residents to Eat Right, Move More and ... Milk ... by the,ups and downs of different fad diets -- which seem to go ... been,slim. Two out of three Americans remain overweight or obese., A new ...
... and Indiana Fever for an evening of celebration, INDIANAPOLIS, ... will be honored by the March of Dimes on June ... collaboration to help families,with critically ill babies throughout the state ... walk., For several years, Anthem has teamed up with ...
... enable sexual maturity and fertility make a critical journey: from ... the brain. , They believe their studies in the ... neurons don,t make it and enable better ways to help ... "They can go to the right place but take too ...
Cached Medicine News:Health News:CMS Selects Thomson Reuters to Help Detect Medicaid Fraud in Eight States 2Health News:Genomics of Cardiovascular Disease: Current Clinical Applications 2Health News:Primary care visits reduce hospital utilization among Medicare beneficiaries at the end of life 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Anthem Blue Cross and Blue Shield Honored by March of Dimes 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 3
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: